Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyridostigmine Bromide in SMA Type 3
NCT02227823Phase 2Completed
- Sponsor
- CHR de la Citadelle
- Start
- Jul 2014
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pyridostigmine in Spinal muscular atrophy type 3 (SMA3) (2 arms), sponsored by CHR de la Citadelle. Primary endpoint: Change from Baseline in the distance walked at 6-minute walk test. Started Jul 2014; status: completed.
02
Drugs
pyridostigmine
03
Conditions
Spinal muscular atrophy type 3 (SMA3)
Beyond the preview
Go deeper on NCT02227823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227823.